Stockwatch: UniQure's guile and the dubious promise of gene therapy
This article was originally published in Scrip
After last week's headline-grabbing deal between Bristol Myers Squibb (BMS) and Dutch gene therapy company uniQure (scripintelligence.com, 6 April 2015), who would have thought that events in Europe might by the end of the week spell the demise of uniQure's gene therapy platform?
You may also be interested in...
Last year's platform failure and back to the drawing board status of bluebird bio was all forgotten last week as data on a few patients treated with its CAR-T therapy were released. It seems that investors are quick to forget similar failed or problematic products at Arrowhead, uniQure and Juno.
The impact of the coronavirus pandemic on investors’ portfolios was immediately apparent at the end of the first quarter of 2020. Equity market sell-offs are reflections of investors’ concern for future financial performance which, if material, may have to be announced early.
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.